Expansion opportunities Eurofins Viracor has recently expanded facilities in Lenexa, Kansas, signaling capacity growth and regional service expansion. This creates cross-sell opportunities for additional infectious disease and transplant testing panels in the Midwest and adjacent regions.

CAR T testing enablement The launch of ExPeCT anti-CD19 CAR T-cell assay positions Viracor as a partner for monitoring CAR T therapies. Target biopharma companies and transplant centers offering CAR T approaches can benefit from alliance on companion diagnostics and post-infusion monitoring.

T-cell immunity solutions introduction of BKV inSIGHT T-Cell Immunity Panel opens a path to expand testing menus for immunocompromised patients and post-transplant surveillance, enabling bundled testing strategies for institutions managing high-risk patient cohorts.

Broad infectious disease portfolio Recent launches including Pneumococcal 21-valent Conjugate Vaccine IgG multiplex and quantitative PCR for Chagas and dimorphic fungi enhance the reference lab’s capability to support vaccine response assessment and broad infectious disease diagnostics—opportunities for hospital networks and diagnostics marketplaces seeking comprehensive panels.

Strategic partnerships With a robust tech stack and experience serving medical professionals, transplant teams, and biopharma, Viracor can be positioned as a preferred partner for contract research, clinical trials, and outsourced testing, leveraging capabilities to scale with customer demand.